Literature DB >> 2548768

Long-term beta-blockade in dilated cardiomyopathy. Effects of short- and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol.

F Waagstein1, K Caidahl, I Wallentin, C H Bergh, A Hjalmarson.   

Abstract

To evaluate the short- and long-term effects of beta-adrenergic blockade (metoprolol) as well as the reaction to withdrawal and readministration of metoprolol in severe heart failure, 33 patients (25 men and eight women; mean age, 47.6 +/- 14.0 years) with dilated cardiomyopathy were studied by right and left heart catheterization, right ventricular biopsy, two-dimensional and Doppler echocardiography, and external pulse recordings. Twenty-six of 33 patients survived more than 6 months, and 24 of the 26 patients improved their functional class (from mean 3.3 to 1.8, p less than 0.0001). These 24 patients were subjected to withdrawal of metoprolol until the number of symptoms increased and deterioration occurred as observed noninvasively (group 1, n = 16), whereas the eight patients did not deteriorate during a 12-month period (group 2). During long-term treatment with metoprolol, there was an increase in ejection fraction from 0.24 to 0.42 (p less than 0.0001), whereas there was a decrease in the left ventricular (LV) end-diastolic dimension (from 7.3 to 6.4 cm, p less than 0.0001), in the grade of mitral regurgitation (from 1.7 to 0.4, p less than 0.0001), and in the grade of tricuspid regurgitation (from 0.6 to 0.05, p less than 0.007). There was a decrease in pulmonary wedge pressure (from 23.8 to 10.7 mm Hg, p less than 0.0001), LV end-diastolic pressure (from 24.1 to 13.4 mm Hg, p less than 0.002), and systolic vascular resistance (from 1,782 to 1,499 dynes/sec/cm, p less than 0.04). There was an increase in systolic blood pressure (from 116 to 132 mm Hg, p less than 0.003), cardiac index (from 2.17 to 2.58 l/min/m2, p less than 0.005), and LV stroke work index (from 31 to 65 g.m/m2, p less than 0.0001). During withdrawal of metoprolol, the heart rate and left atrial dimension increased (p less than 0.0001), whereas ejection fraction decreased (p less than 0.0001). The 12 (of 16) patients in group 1 who survived the withdrawal period had metoprolol readministered, and subsequently, ejection fraction increased (from 0.23 to 0.33, p less than 0.002). Patients had a low number of ventricular beta-adrenergic receptors compared with healthy control subjects (30.3 +/- 2.9 vs. 97.4 +/- 8.7 fmol/mg protein, p less than 0.001), but long-term treatment with metoprolol caused a moderate up-regulation (from 30.3 +/- 2.9 to 49.0 +/- 7.1 fmol/mg protein, p less than 0.05), which may facilitate a more normal response to sympathetic stimulation.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2548768     DOI: 10.1161/01.cir.80.3.551

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  75 in total

1.  Managing congestive heart failure medically--what have we learned?

Authors:  K Chatterjee
Journal:  West J Med       Date:  1990-10

2.  [Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany].

Authors:  P K Schädlich; B Paschen; J G Brecht
Journal:  Med Klin (Munich)       Date:  1997-08-15

Review 3.  Alterations in adrenergic receptor signaling in heart failure.

Authors:  S Lamba; W T Abraham
Journal:  Heart Fail Rev       Date:  2000-03       Impact factor: 4.214

Review 4.  Reversal of maladaptive gene program in left ventricular myocardium of dogs with heart failure following long-term therapy with the Acorn Cardiac Support Device.

Authors:  Sharad Rastogi; Sudhish Mishra; Ramesh C Gupta; Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2005-06       Impact factor: 4.214

Review 5.  Left ventricular histomorphometric findings in dogs with heart failure treated with the Acorn Cardiac Support Device.

Authors:  Victor G Sharov; Anastassia V Todor; Hani N Sabbah
Journal:  Heart Fail Rev       Date:  2005-06       Impact factor: 4.214

Review 6.  Therapy of idiopathic dilated cardiomyopathy with chronic beta-adrenergic blockade.

Authors:  E M Gilbert; J B O'Connell; M R Bristow
Journal:  Heart Vessels Suppl       Date:  1991

7.  The effect of beta-adrenergic blockade in dilated cardiomyopathy--a questionnaire study in Japan.

Authors:  A Matsumori; M Tominaga; S Handa; Y Fukuchi; A Kitabatake; H Matsuo; S Matsuo; J Mihune; T Nakano; S Nobuoka
Journal:  Heart Vessels Suppl       Date:  1991

Review 8.  Recent developments in the treatment of congestive heart failure.

Authors:  W B Hood
Journal:  Trans Am Clin Climatol Assoc       Date:  1991

9.  Changing mortality in dilated cardiomyopathy. The Heart Muscle Disease Study Group.

Authors:  A Di Lenarda; G Secoli; A Perkan; D Gregori; G Lardieri; B Pinamonti; G Sinagra; M Zecchin; F Camerini
Journal:  Br Heart J       Date:  1994-12

10.  Chronic β1-adrenergic blockade enhances myocardial β3-adrenergic coupling with nitric oxide-cGMP signaling in a canine model of chronic volume overload: new insight into mechanisms of cardiac benefit with selective β1-blocker therapy.

Authors:  Danielle M Trappanese; Yuchuan Liu; Ryan C McCormick; Alessandro Cannavo; Gayani Nanayakkara; Marina M Baskharoun; Harish Jarrett; Felix J Woitek; D Michael Tillson; A Ray Dillon; Fabio A Recchia; Jean-Luc Balligand; Steven R Houser; Walter J Koch; Louis J Dell'Italia; Emily J Tsai
Journal:  Basic Res Cardiol       Date:  2014-12-06       Impact factor: 17.165

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.